AstraZeneca ups yields but takes $400m hit on plant closures
“We can produce the volume we need with more limited manufacturing capacity,” says AstraZeneca in the wake of closing two biologics facilities in Colorado. Last month, AstraZeneca announced plans to consolidate its US biologics manufacturing operations. This included closing facilities in Bou ...
AI, regenerative medicine enabling technologies, and clinical diagnostics are major investment opportunities, says life science executive Reinhar ...
CDMO AGC Biologics will develop the process and manufacture Calypso’s CALY-002, a humanized monoclonal antibody manufactured in a CHO cell line ...
AveXis has spent about $1 billion in preparing to launch its spinal muscular atrophy (SMA) gene therapy later this year. The Novartis subsidiary ...
The US FDA found antibody-drug conjugate developer Immunomedics to have manipulated data during an inspection last year.
In January 2019, the ...
Recent Tweets
-
RT @Dan5tanton: #AveXis has spent about $1 billion in preparing to launch its spinal muscular atrophy (#SMA) #genetherapy later thi… https://t.co/nOWUlDLKqo
2 days ago
-
RT @Dan5tanton: “We can produce the volume we need with more limited manufacturing capacity,” says #AstraZeneca in the wake of clos… https://t.co/t4kgnPc669
6 days ago
-
RT @Dan5tanton: Following Novartis and Gilead’s success, others are “scrambling to build up their T-Cell capabilities,” say venture… https://t.co/7zJuWL0uGN
1 week ago
-
#CDMO WuXi Biologics will harness its growing global network to supply the commercial drug substance and product fo… https://t.co/zpkjaCQqsS
1 week ago
Trending
2019
Biosimilars: Challenging the Justifications for Clinical Testing
Upstream Processing
A Brief History of Adherent Cell Culture: Where We Come From and Where We Should Go
Manufacturing
The Changing Landscape of Single Use in Bioprocessing: An Interview with Stefan Schlack and Jean-Marc Cappia
Analytical
Qualitative and Quantitative Host Cell Protein Analysis Using Mass Spectrometry